Jeffrey D. Alexis

Jeffrey D. Alexis

Auto-generated profile, based on publicly available information

Jeffrey D. Alexis

Division of Cardiology and Cardiothoracic Surgery, and the Clinical Cardiovascular Research Center, University of Rochester School of Medicine and Dentistry

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2022 in The American Journal of Cardiology
Verified
Journal Article
Closed access
HVHimabindu Vidula
Himabindu Vidula
OAOnur Altintas
Onur Altintas
SMScott McNitt
Scott McNitt
ADAdam David DeVore
Adam David DeVore
EBEdo Y. Birati
Edo Y. Birati
IGIlan Goldenberg
Ilan Goldenberg

3 March 2025 in ASAIO Journal
Verified
Journal Article
Closed access
JAJeffrey D. Alexis
Jeffrey D. Alexis
KWKatherine Wood
Katherine Wood
IGIgor Gosev
Igor Gosev
AJAnas Jawaid
Anas Jawaid
LCLeway Chen
Leway Chen
IGIlan Goldenberg
Ilan Goldenberg
As questions remain about the risk–benefit of left ventricular assist device (LVAD) therapy, we evaluated the association between LVAD versus medical therapy for the competing risk of all-cause mortality and all-cause readmission. Among consecutive patients evaluated for advanced heart failure (HF) therapy, 260 were referred for LVAD implantation and 292 continued medical therapy in this retrospective, observational database study. At 2 years, all-cause mortality was significantly higher among medically managed patients versus LVAD recipients (37% vs. 25%, p = 0.014). Separation in event rates appeared within 3 months and was sustained throughout follow-up. The cumulative incidence rate of all-cause readmissions at 2 years was higher among LVAD recipients (78% vs. 40%, p < 0.001). In multivariate analysis, compared with medical therapy, LVAD therapy was associated with a significant 35% lower risk of death (p = 0.005), driven by a 57% reduction in the risk of death within the first 3 months (p < 0.001), and a 2.8-fold increased risk of readmission. Among medically managed patients, lower baseline hemoglobin and blood pressure, older age, and increased creatinine were predictors of death. In conclusion, among patients with advanced HF, LVAD therapy was associated with pronounced survival benefit, but a higher 2-year readmission rate compared with medical management.

1 June 2019 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
PMPrateek Mathur
Prateek Mathur
DMDanielle Marino
Danielle Marino
KBKrystle Bittner
Krystle Bittner
NBNicholas Bartell
Nicholas Bartell
CTCaren Taylor
Caren Taylor
SKShivangi T. Kothari
Shivangi T. Kothari

25 September 2008 in Journal of Vascular Research
Verified
Journal Article
Open access
PDF file
ALAntoine Lafont
Antoine Lafont
JAJeffrey D. Alexis
Jeffrey D. Alexis
RPRobert T. Pyo
Robert T. Pyo
ICIgor Chereshnev
Igor Chereshnev
JKJonathan Katz
Jonathan Katz
Yong-Xiao WangYong-Xiao Wang
Yong-Xiao Wang

28 April 2022 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
HVHimabindu Vidula
Himabindu Vidula
CDCraig Dennison
Craig Dennison
ZSZsuzsanna Sziveri
Zsuzsanna Sziveri
JAJeffrey Alexis
Jeffrey Alexis
IGIgor Gosev
Igor Gosev
IGIlan Goldenberg
Ilan Goldenberg